Committees : Surrey & Sussex Area Prescribing Committee (APC)

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

The Surrey & Sussex Integrated Care Board Area Prescribing Committee (APC) approved a BLUE formulary status for sodium zirconium cyclosilicate (Lokelma®) for persistent hyperkalaemia in people with CKD stage 3b to 5 or heart failure, noting that its use for acute life-threatening hyperkalaemia remains as RED.

The specialist team will initiate treatment and provide at least 3 months supply before any request is made to transfer prescribing responsibility to Primary Care.

The Surrey & Sussex Integrated Care Board Area PrescribingCommittee (APC) approved the betula verrucosa (Itulazax®) information sheet for clinicians and its host on both Surrey and Sussex formularies. 

A BLUE (with specialist team initiation) traffic light status has been agreed with at least 3 months prescribing by the specialist team to enable a review and confirmation of clinical benefit, prior to any request to transfer prescribing responsibility to Primary Care.

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & sUSSEX Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & Sussex Area Prescribing Committee approved the updated Stoma Accessory Formulary noting that:

• cost effective choices should be used first-line
• approved formulary products should be initiated by the specialist Stoma Teams

Refer to Guideline Profile : Stoma - surrey.res.services for:

• a full list of agreed products (in the Stoma Accessory Formulary)
• recommended prescribing quantities
• contact details for local stoma care teams (in the Stoma Accessory Formulary)

The Surrey & Sussex Integrated Care Board Area Prescribing Committee (APC) approved the addition of prazosin for PTSD (third-line) to the formulary with a BLUE formulary status (specialist initiation and supply for at least one month).

The Surrey & Sussex Integrated Care Board Area Prescribing Committee (APC) approved the Terms of Reference for the Surrey and Sussex Wound Management Prescribing Committee, which will operate as a formal subcommittee of the Surrey and Sussex Area Prescribing Committee.

The Committee noted that the Wound Management Committee would provide specialist oversight of wound care formulary decisions, supporting consistent prescribing practice, clinical effectiveness and value across Surrey and Sussex. Discussion focused on committee membership, including representation from acute providers, and the importance of maintaining appropriate links with commissioning arrangements where formulary decisions may have wider service implications.

Whilst the APC supported the proposed governance arrangements, it was recognised that the operation of the new subcommittee should be reviewed after an initial
period to ensure that membership, voting arrangements and reporting structures remained appropriate.

The Surrey & Sussex APC approved atogepant for acute treatment of migraine in line with recommendations made in NICE TA1172.

 Atogepant for this indication will be considered as GREEN on the traffic light system for patients if, in previous migraines:

• at least 2 triptans were tried and they did not work well enough, or
• triptans were contraindicated or not tolerated, and nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol were tried but did not work well enough

The Surrey and Sussex Integrated Care Board Aprea Prescribing Committee supports restricted use of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in adults, in line with NICE TA1143, where hormone replacement therapy (HRT) is not suitable

The Surrey and Sussex Integrated Care Board Area Prescribing Committee supports use in line with NICE TA1142 as an add-on maintenance treatment for adults with uncontrolled COPD characterised by raised blood eosinophils, where disease remains inadequately controlled despite optimised inhaled therapy.

The Surrey and Sussex Integrated Care Board Aread Prescribing Committee supports restricted use of topical ruxolitinib for the treatment of non-segmental vitiligo with facial involvement in patients aged ≥12 years, in line with NICE TA1140, where standard topical therapies (e.g. potent corticosteroids and/or calcineurin inhibitors) are ineffective, not tolerated, or not appropriate.

Use should be initiated and supervised by a specialist dermatologist with experience in vitiligo management.

Agreement by Chair's Action to change the formulary Traffic Light Status from AMBER to BLUE.

Agreement by Chair's Action, following consultation, to change the formulary Traffic Light Status from AMBER to BLUE.

Agreement by Chair's Action, following consultation, to change the formulary Traffic Light Status from AMBER to BLUE.

Agreement by Chair's Action, following consultation, to change the formulary Traffic Light Status from AMBER to BLUE.

Agreement by Chair's Action, following consultation, to change the formulary Traffic Light Status from AMBER to BLUE.

Agreement by Chair's Action, following consultation, to change the formulary Traffic Light Status from AMBER to BLUE.